STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRTX
  4. [Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity

[Form 4] VERTEX PHARMACEUTICALS INC / MA Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Mark E. Bunnage reported a mix of stock sales, awards, and tax-related share dispositions. He sold 1,182 shares of common stock at $473.68 per share and 2,437 shares at $489.46 per share in open-market transactions.

He also acquired 2,584 shares through a restricted stock unit award that will vest in installments beginning on February 20, 2027, and disposed of 1,110 shares at $483.75 per share to cover tax obligations. These trades were made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025. Following the last reported transaction, he held 8,486 shares of Vertex common stock directly.

Positive

  • None.

Negative

  • None.
Insider Bunnage Mark E.
Role EVP, Chief Scientific Officer
Sold 3,619 shs ($1.75M)
Type Security Shares Price Value
Sale Common Stock 1,182 $473.68 $560K
Grant/Award Common Stock 2,584 $0.00 --
Tax Withholding Common Stock 1,110 $483.75 $537K
Sale Common Stock 2,437 $489.46 $1.19M
Holdings After Transaction: Common Stock — 8,486 shares (Direct)
Footnotes (1)
  1. Restricted stock unit award that vests in installments beginning on February 20, 2027. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bunnage Mark E.
(Last) (First) (Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
(Street)
BOSTON MA 02210
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 A 2,584(1) A $0 13,215 D
Common Stock 02/17/2026 F 1,110 D $483.75 12,105 D
Common Stock 02/17/2026 S(2) 2,437 D $489.46 9,668 D
Common Stock 02/18/2026 S(2) 1,182 D $473.68 8,486 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted stock unit award that vests in installments beginning on February 20, 2027.
2. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR